Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$118.49

0.93 (0.79%)

, PFE

Pfizer

$32.50

-0.16 (-0.49%)

17:49
10/17/16
10/17
17:49
10/17/16
17:49

J&J trades lower after Pfizer announces availability of Remicade biosimilar

Shares of Johnson & Johnson (JNJ) are fractionally lower, down 0.41%, or 49c to $118 per share in after-hours trading after Pfizer (PFE) announced that the company will begin shipment of INFLECTRA for injection, a biosimilar of REMICADE to wholesalers in the United States in late November 2016.

JNJ

Johnson & Johnson

$118.49

0.93 (0.79%)

PFE

Pfizer

$32.50

-0.16 (-0.49%)

  • 18

    Oct

  • 22

    Oct

  • 26

    Oct

  • 01

    Nov

  • 06

    Nov

JNJ Johnson & Johnson
$118.49

0.93 (0.79%)

08/24/16
JEFF
08/24/16
NO CHANGE
Target $210
JEFF
Buy
Cooper Companies estimates raised at Jefferies after doctor survey
Jefferies analyst Anthony Petrone reports that the firm's survey of 52 new optometry practices suggest continued gains in dailies and stable share in monthlies for Cooper Companies (COO) and that Johnson & Johnson's (JNJ) Acuvue Vita is off to slow start. Based on the survey results, and a "significant" foreign exchange tailwind, Petrone raised his estimates for Cooper and increased his price target on the shares to $210 from $190. The firm has a Buy rating on Cooper shares.
09/19/16
JEFF
09/19/16
NO CHANGE
Target $48
JEFF
Buy
Abbott unit sale does not impact Alere transaction, says Jefferies
Jefferies analyst Jeffrey Holford believes Abbott's (ABT) sale of its Medical Optics business to Johnson & Johnson (JNJ) does not imply an increased probability that the Alere (ALR) deal will close. After speaking to Abbott management, Holford thinks the proceeds from the sale are more likely to be targeted towards the St. Jude Medical (STJ) acquisition. He believes that deal has a higher probability of closing than Alere. Holford has a Buy rating on Abbott with a $48 price target.
09/19/16
LEER
09/19/16
NO CHANGE
LEER
Abbott, Johnson & Johnson transaction positive for both companies, says Leerink
Leerink analyst Danielle Antalffy says the sale of Abbott's (ABT) Medical Optics ophthalmology business to Johnson & Johnson (JNJ) is positive for both companies. The deal strengthens Abbott's balance sheet and eliminates the need for a previously expected $3B capital raise, and adds a key component to Johnson & Johnson's already-strong vision care franchise, the analyst notes.
10/07/16
RBCM
10/07/16
NO CHANGE
RBCM
Johnson & Johnson weakness creates buying opportunity, says RBC Capital
RBC Capital analyst Glenn Novarro says that Johnson & Johnson underperformed the market in Q3 due to a number of factors including Remicade biosimilar risk and the pharma pricing debate. The analyst says that "these concerns are manageable/overblown," and he expects the company to report strong Q3 results, driven by a strong pharma performance. Novoroo expects the company's Q3 revenue to come in slightly above expectations, and he predicts that the company will narrow its 2016 EPS guidance to the high end of the previous range. The analyst recommends buying the stock. He keeps a $133 price target and Outperform rating on the shares.
PFE Pfizer
$32.50

-0.16 (-0.49%)

09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
10/13/16
10/13/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

OCLR

Oclaro

$9.72

-1.25 (-11.39%)

20:45
02/22/17
02/22
20:45
02/22/17
20:45
Conference/Events
Oclaro management to meet with Jefferies »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 03

    Mar

GMS

GMS Inc.

$29.79

-0.52 (-1.72%)

20:32
02/22/17
02/22
20:32
02/22/17
20:32
Syndicate
GMS Inc. 6.95M share Secondary priced at $29.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

APA

Apache

$54.91

-0.98 (-1.75%)

, HRL

Hormel Foods

$37.30

-0.3 (-0.80%)

20:25
02/22/17
02/22
20:25
02/22/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

APA

Apache

$54.91

-0.98 (-1.75%)

HRL

Hormel Foods

$37.30

-0.3 (-0.80%)

KSS

Kohl's

PF

Pinnacle Foods

$54.63

-0.61 (-1.10%)

CHK

Chesapeake

$5.92

-0.16 (-2.63%)

CNK

Cinemark

$43.39

0.51 (1.19%)

AMCX

AMC Networks

$57.50

-0.19 (-0.33%)

W

Wayfair

$41.26

1 (2.48%)

SFM

Sprouts Farmers Markets

$19.00

-0.32 (-1.66%)

TREE

LendingTree

$112.15

-1.45 (-1.28%)

TXMD

TherapeuticsMD

$5.67

0.08 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 01

    Mar

  • 06

    Mar

  • 16

    Mar

  • 19

    Mar

  • 21

    Mar

  • 28

    Mar

  • 07

    May

  • 11

    May

FIT

Fitbit

$5.88

-0.16 (-2.65%)

20:14
02/22/17
02/22
20:14
02/22/17
20:14
Hot Stocks
Fitbit CEO says early adopter segment saturated, says exploring new form factors »

Speaking during the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

SQ

Square

$15.04

0.41 (2.80%)

19:57
02/22/17
02/22
19:57
02/22/17
19:57
Upgrade
Square rating change  »

Square upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

FIT

Fitbit

$5.88

-0.16 (-2.65%)

19:50
02/22/17
02/22
19:50
02/22/17
19:50
Hot Stocks
Fitbit says paid $23M for Pebble assets »

Fitbit disclosed in its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

SBUX

Starbucks

$57.57

0.03 (0.05%)

19:34
02/22/17
02/22
19:34
02/22/17
19:34
Hot Stocks
Market researcher: Starbucks consumer perception dips after refugee hiring news »

Market researcher YouGov…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

LB

Labarge

$58.13

0.43 (0.75%)

19:33
02/22/17
02/22
19:33
02/22/17
19:33
Hot Stocks
L Brands sees Q1 comps down high-single to low-double digits »

Sees Q1 Go-Forwards comps…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

LB

Labarge

$58.13

0.43 (0.75%)

19:32
02/22/17
02/22
19:32
02/22/17
19:32
Hot Stocks
L Brands sees FY17 comps down low-single digits »

Sees FY17 Go-Forward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

F

Ford

$12.67

-0.02 (-0.16%)

19:30
02/22/17
02/22
19:30
02/22/17
19:30
Conference/Events
Ford to host sales conference call »

Ford U.S. Sales Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

GTLS

Chart Industries

$38.51

-1.21 (-3.05%)

19:27
02/22/17
02/22
19:27
02/22/17
19:27
Hot Stocks
Chart Industries CEO Samuel Thomas named executive chairman »

According to a regulatory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$273.51

-3.88 (-1.40%)

19:24
02/22/17
02/22
19:24
02/22/17
19:24
Periodicals
SolarCity leased with risky homeowners, has ties to foreclosure cases, NYT says »

In "dozens of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

PRU

Prudential

$110.50

-0.72 (-0.65%)

, WFC

Wells Fargo

$58.36

0.11 (0.19%)

19:16
02/22/17
02/22
19:16
02/22/17
19:16
Hot Stocks
Prudential says could seek compensation from Wells Fargo over MyTerm products »

Prudential (PRU) stated…

PRU

Prudential

$110.50

-0.72 (-0.65%)

WFC

Wells Fargo

$58.36

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Mar

  • 13

    Apr

  • 06

    Jun

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

PSA

Public Storage

$226.24

-1.49 (-0.65%)

19:15
02/22/17
02/22
19:15
02/22/17
19:15
Earnings
Public Storage reports Q4 core FFO $2.65, consensus $1.89 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

CS

Credit Suisse

$15.35

-0.13 (-0.84%)

19:10
02/22/17
02/22
19:10
02/22/17
19:10
Periodicals
Credit Suisse probed for potentially aiding tax evasion, WSJ says »

Less than three years…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

LZB

La-Z-Boy

$28.40

-1.05 (-3.57%)

19:09
02/22/17
02/22
19:09
02/22/17
19:09
Downgrade
La-Z-Boy rating change  »

La-Z-Boy downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

CLD

Cloud Peak

$5.68

-0.19 (-3.24%)

19:06
02/22/17
02/22
19:06
02/22/17
19:06
Syndicate
Cloud Peak 13.5M share Spot Secondary priced at $5.10 »

Credit Suisse, JPMorgan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

SNAP

Snap Inc

18:47
02/22/17
02/22
18:47
02/22/17
18:47
Periodicals
Snap Inc nears $200M ad deal, NY Post says »

Snap Inc is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

SBLK

Star Bulk Carriers

$9.59

0.29 (3.12%)

18:40
02/22/17
02/22
18:40
02/22/17
18:40
Earnings
Star Bulk Carriers reports Q4 EPS (29c), consensus (28c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 22

    Mar

C

Citi

$60.62

0.07 (0.12%)

18:35
02/22/17
02/22
18:35
02/22/17
18:35
Periodicals
Citi forms regulatory affairs team in D.C., Bloomberg says »

Citi is forming a global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:34
02/22/17
02/22
18:34
02/22/17
18:34
Earnings
PRA Health sees FY17 EPS $3.08-$3.18, consensus $2.96 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

, ATH

Athene Holding

$51.45

0.38 (0.74%)

18:32
02/22/17
02/22
18:32
02/22/17
18:32
Periodicals
Fidelity & Guaranty Life revives sale process, Insurance Insider says »

Fidelity & Guaranty…

FGL

Fidelity & Guaranty Life

$26.30

-0.1 (-0.38%)

ATH

Athene Holding

$51.45

0.38 (0.74%)

APO

Apollo Global

$22.25

0.05 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

PRAH

PRA Health

$59.98

-0.71 (-1.17%)

18:31
02/22/17
02/22
18:31
02/22/17
18:31
Earnings
PRA Health sees Q1 EPS 57c-62c, consensus 67c »

Sees Q1 service revenues…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

NBR

Nabors Industries

$15.44

0.01 (0.06%)

18:30
02/22/17
02/22
18:30
02/22/17
18:30
Earnings
Nabors Industries reports Q4 EPS ($1.17) with items »

Q4 EPS includes 87c in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

AXGN

AxoGen

$10.50

-0.1 (-0.94%)

18:28
02/22/17
02/22
18:28
02/22/17
18:28
Earnings
AxoGen reiterates FY17 revenue growth view of at least 40% »

Management reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

  • 21

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.